Amundi Decreases Stake in Edwards Lifesciences Corporation $EW

Key Points

• Amundi reduced its Edwards Lifesciences stake by 3.4% in the second quarter, selling 90,461 shares and retaining 2.58 million shares valued at about $233.4 million. Institutional investors collectively own 79.46% of the company.
• Wall Street remains broadly optimistic, with 17 Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $100.27, above the stock’s reported $86.73 price.
• Edwards exceeded quarterly expectations, reporting $0.78 EPS and $1.74 billion in revenue, with revenue up 13.6% year over year. Company guidance calls for full-year 2026 EPS of $2.95–$3.05, while insiders sold 5,045 shares worth approximately $457,749 over the prior three months.

Amundi lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,579,748 shares of the medical research company's stock after selling 90,461 shares during the quarter. Amundi owned 0.45% of Edwards Lifesciences worth $233,364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Rehmann Capital Advisory Group boosted its holdings in shares of Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after buying an additional 130 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock worth $1,288,000 after acquiring an additional 136 shares during the last quarter. Stephens Inc. AR raised its stake in Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock valued at $239,000 after acquiring an additional 144 shares during the period. Aspen Investment Management Inc raised its position in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock valued at $885,000 after purchasing an additional 150 shares during the period. Finally, Covestor Ltd raised its holdings in Edwards Lifesciences by 9.6% during the 4th quarter. Covestor Ltd now owns 1,784 shares of the medical research company's stock valued at $152,000 after acquiring an additional 157 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Citigroup raised their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. UBS Group started coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 target price for the company. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research note on Thursday, July 16th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the firm's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock worth $457,749 in the last three months. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

EW stock opened at $86.73 on Wednesday. The firm has a market cap of $49.94 billion, a P/E ratio of 49.85, a P/E/G ratio of 2.36 and a beta of 0.85. The firm's fifty day moving average is $89.63 and its 200 day moving average is $85.70. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the business posted $0.67 earnings per share. The company's revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.